Shockwave Therapy vs. Corticosteroid Injection for Greater Trochanteric Pain Syndrome .
Greater trochanteric pain syndrome: focused shockwave therapy versus an ultrasound guided injection: a randomised control trial.
Hip Int. 2023 May;33(3):490-499.104 patients with greater trochanteric pain syndrome were randomized to receive an injection of corticosteroid (n=51) or 3 weekly sessions of focused extracorporeal shockwave therapy (f-ESWT; n=53). The primary outcome of interest was pain on a Visual Analog Scale (VAS). Secondary outcomes of interest included the Harris Hip Score (HHS), the Trendelenberg test for function, quality of life on the Short-Form 36 (SF-36) scale, and perceived symptom change. All outcomes were assessed at 3 and 12 months post-operation. F-ESWT demonstrated significant advantages over corticosteroid injection, provided superior pain improvement, function scores, mental health quality of life scores, hip abductor function, and perceived change at 12 months. Similar outcomes were observed at 3 months, suggesting comparable outcome improvement in the early phase with superior long-term efficacy with f-ESWT.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics